Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.52 |
| ▸ | BCL9 | O00512 | 6/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16354314 | 0.81 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL3777801 | 0.81 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL912286 | 0.81 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL20165032 | 0.79 | ALDH1A1 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL20165033 | 0.79 | ALDH1A1 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL3133910 | 0.77 | PARP10 (0.64) | CHRNB2CHRNA4 | |
| SCHEMBL240882 | 0.77 | GAA (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL4449045 | 0.76 | KMT2A (0.50) | KMT2A | |
| Hydrochloric Acid SCHEMBL3127575 | 0.76 | PARP10 (0.62) | CHRNB2CHRNA4BCL9CTNNB1 | |
| SCHEMBL237663 | 0.75 | GAA (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | CHRNB2 2194/4885CHRNB4 2315/4885CHRNA3 2838/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | CHRNB2 2346/4885CHRNB4 2459/4885CHRNA3 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.